• Featured Product
  • KD/KO Validated

PCSK9 Polyclonal antibody

PCSK9 Polyclonal Antibody for WB, IHC, ELISA

Host / Isotype

Rabbit / IgG


human, rat and More (1)





Cat no : 55206-1-AP


FH3, HCHOLA3, LDLCQ1, NARC 1, NARC1, PC9, PCSK9, Proprotein convertase 9

Tested Applications

Positive WB detected inCOLO 320 cells, HepG2 cells, SMMC-7721 cells
Positive IHC detected inhuman colon cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:3000
Immunohistochemistry (IHC)IHC : 1:250-1:1000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

55206-1-AP targets PCSK9 in WB, IP, IF, IHC, ChIP, ELISA applications and shows reactivity with human, rat samples.

Tested Reactivity human, rat
Cited Reactivityhuman, rat, hamster
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Peptide
Full Name proprotein convertase subtilisin/kexin type 9
Calculated Molecular Weight 74 kDa
Observed Molecular Weight 58-62 kDa, 72-78 kDa
GenBank Accession NumberNM_174936
Gene Symbol PCSK9
Gene ID (NCBI) 255738
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)


Product Specific Protocols
WB protocol for PCSK9 antibody 55206-1-APDownload protocol
IHC protocol for PCSK9 antibody 55206-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols




Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.

Authors - Xinjian Liu
  • KO Validated

J Nanobiotechnology

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

Authors - Zhenxian Li

Biomed Pharmacother

Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases

Authors - Hui-Hui Guo

Front Immunol

PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer

Authors - Xiang Gao

Int J Mol Sci

Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity

Authors - Po-Wei Chen

Int J Mol Sci

Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells.

Authors - Chiara Barisione


The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.


Malak (Verified Customer) (11-30-2020)

The antibody works very well in IHC staining especially at pH6 and 1/100 dilution

  • Applications: Immunohistochemistry
  • Primary Antibody Dilution: 1/100
  • Cell Tissue Type: Hepatic tissue